Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib plus docetaxel versus placebo plus docetaxel in KRAS-negative advanced non-small cell lung cancer
NL-OMON40353Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Selumetinib + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: Progression-free survival. Planned start Aug 2013; status: not yet recruiting.
02
Drugs
selumetinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON40353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40353.